What is Absci Corp?
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.30B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 112,900 shares $149k |
| 6-9months | 0 | 3212,548 shares $636k |
| 9-12months | 244,257 shares $132k | 140,000 shares $149k |